Liver Transplantation in a Patient with Pulmonary Hypertension at High Altitude
β Scribed by Kefeng Dou; Desheng Wang; Qingchuan Zhao; Zhenshun Song; Shuqiang Yue; Kaishan Tao; Shaoyang Chen; Yong He; Zhenyu Ti
- Publisher
- Elsevier Science
- Year
- 2010
- Tongue
- English
- Weight
- 121 KB
- Volume
- 21
- Category
- Article
- ISSN
- 1080-6032
No coin nor oath required. For personal study only.
β¦ Synopsis
Chronic hypoxia at high altitude stresses many of the body's homeostatic mechanisms. As a consequence, the body develops alveolar hypoxia, hypoxemia, and polycythemia, which in turn causes vasoconstriction, pulmonary hypertension, and an increased risk of atherothrombotic complications. We report a successful liver transplantation in a patient with pulmonary hypertension who lives 4500 m above sea level. Pulmonary hypertension and hypercoagulable state induced by chronic hypoxia at high altitude may increase the risk of cardiopulmonary complication and perioperative mortality. The patient was discharged in good condition with normal liver function at the 34th postoperative day. After 41 months of follow-up, the patient is alive and well with a continued normalization of hepatic function and is continuing to live at 4500 m above sea level.
π SIMILAR VOLUMES
Clinical prediction of portopulmonary hypertension (PPHTN) is critical in the preoperative evaluation of candidates for orthotopic liver transplantation (OLT) because of its association with significant morbidity and mortality. To determine the clinical, laboratory, and echocardiographic predictors
## Abstract This is a report of the echocardiographic findings in a 9βyearβold white female with primary pulmonary arterial hypertension confirmed by catheterization and later at autopsy. The reported findings of an absent βaβ wave, a flat diastolic E to F slope, and a midsystolic closure of the pu
Pulmonary arterial hypertension associated with portal hypertension occurs in about 5% of patients being evaluated for liver transplantation. Treatment is required to facilitate safe transplantation, and oral pulmonary vasodilators have yet to be prospectively evaluated for this disease. The objecti